93892-06-9

Usage

Uses

Used in Medical Applications:
Ethyl 8-hydroxyoctanoate is used as a reagent for the site-specific radiofluorination of biomolecules. This process is essential for the development of diagnostic and therapeutic agents, as it allows for the precise labeling of biologically active molecules with radioactive isotopes. This enables researchers and medical professionals to track the distribution and metabolism of these molecules within the body, as well as to evaluate the effectiveness of potential treatments.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Ethyl 8-hydroxyoctanoate plays a vital role in the synthesis of various drugs and drug candidates. Its unique chemical properties make it a valuable component in the development of new medications, particularly those targeting specific biological pathways or receptors.
Used in Research and Development:
Ethyl 8-hydroxyoctanoate is also utilized in research and development settings, where it can be employed to study the interactions between biomolecules and their environment. This can provide valuable insights into the mechanisms of action of various biological processes and contribute to the advancement of scientific knowledge in the field of biochemistry and molecular biology.

InChI:InChI=1/C10H20O3/c1-2-13-10(12)8-6-4-3-5-7-9-11/h11H,2-9H2,1H3

Upstream product

• 25542-62-5 6-bromo-hexanoic acid ethyl ester 
• 764-89-6 8-hydroxycaprylic acid 
• 64-17-5 ethanol 
• 5698-29-3 oxonan-2-one 
• 57221-90-6 diethyl 2-<6-(tetrahydro-2H-pyranyloxy)hexyl>malonate 
• 4286-55-9 1-bromo-6-hexanol 
• 53963-10-3 2-[(6-bromohexyl)oxy]tetrahydro-2H-pyran 
• 34067-76-0 6-hydroxyhexanal 
• 502-44-3 hexahydro-2H-oxepin-2-one 
• 821-41-0 5-Hexen-1-ol 
• 4455-13-4 methylthioacetic acid ethyl ester 
• 57221-91-7 ethyl 8-(tetrahydro-2H-pyran-2-yl)oxyoctanoate 
• 75958-95-1 (E)-8-hydroxy-oct-2-enoic acid ethyl ester 
• 54699-43-3 8-(tetrahydro-2'H-pyran-2'-yl-oxy)-1-octanoic acid 

Downstream Products

• 332-97-8 ethyl 8-fluorooctanoate 
• 213267-10-8 S-[7-(3-azidophenyl)heptyl]glutathione 
• 213267-11-9 1-azido-3-(7-bromo-heptyl)-benzene 
• 236754-30-6 7-(3-azido-phenyl)-heptan-1-ol 
• 236754-29-3 7-(3-aminophenyl)-1-heptanol 
• 236754-28-2 ethyl 7-(3-nitrophenyl)-6-heptenoate 
• 144682-03-1 ethyl 8-[[(4-methylphenyl)sulfonyl]oxy]octanoate 

Relevant academic research and scientific papers

SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE

New methodologies for site-specifically radiolabeling proteins with the PET isotope [18F] are required to generate high quality radiotracers for imaging in both the preclinical and clinical settings. The enzymatic radiofluorination overcomes many of the limitations encountered to date with purely chemical approaches. The bacterial enzyme lipoic acid ligase was used to conjugate [18F]-fluorooctanoic acid to both a small peptide and a Fab antibody fragment. Labeling was site-specific and highly efficient under mild aqueous conditions using small amounts of peptide/protein (1-10 nmol). The labeled construct retained full epitope binding affinity and was stable in mouse serum. Using an optimized reaction scheme, mCi quantities of [18F]-Fab were generated, an amount sufficient for human imaging.

DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR

The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor which is applicable to various diseases. When used as an active ingredient, a compound represented by formula (I): (wherein X represents a halogen atom, R1 represents a hydrogen atom, R2 represents an alkyl group containing 1 to 7 carbon atoms, R3 represents -CHO, and R4 represents -CH2-CH=C(CH3)-R0 (wherein R0 represents an alkyl group containing 1 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon, etc.)), an optical isomer thereof or a pharmaceutically acceptable salt thereof has a high inhibitory effect on dihydroorotic acid dehydrogenase and can be used as an immunosuppressive agent, a therapeutic agent for rheumatism, an anticancer agent, a therapeutic agent for graft rejection, an antiviral agent, an anti-H. pylori agent, a therapeutic agent for diabetes or the like.

NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT

Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents -CHO, -C(=O)R5, -COOR5 (wherein R5 represents a C1-7 alkyl group), -CH2OH or -COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.

Reductive bromine atom-transfer reaction

Atom-transfer radical (ATR) reactions of alkenes with R-X usually give products having new C-C and C-X bonds at the adjacent carbons. However, when the reaction was carried out under irradiation using a low-pressure Hg lamp, addition/reduction products were obtained in good yield. Hydrogen bromide, formed by H-abstraction of a bromine radical from alkenes, is likely to play a key role in the reductive ATR reaction.

Potent oligomerization and macrocyclization activity of the thioesterase domain of vicenistatin polyketide synthase

The thioesterase domain of the polyketide synthase involved in the biosynthesis of the 20-membered macrolactam antibiotic vicenistatin (VinTE) was found to catalyze oligomerization and macrocyclization of ω-hydroxy fatty acid ethyl esters to afford 17-28-membered macrocyclic lactones. The ring sizes of the macrocycles appear to be limited to the more moderate sizes because of the space limitation of the active site of VinTE. It was also verified that the initially formed linear dimer is first released from the active site of VinTE and then is recognized again by VinTE prior to its transformation to the cyclic dimer.

A mild and versatile method for the tetrahydropyranylation of alcohols and their detetrahydropyranylation

An efficient and mild method for tetrahydropyranylation of alcohols and their detetrahydropranylation using NH4Cl is described. This protocol provides a useful alternative tetrahydropyranylation of alcohols and their deprotection at different pH.

Tin-free reductive photochemical carboxymethylation of olefins with α- alkylthioacetates

An efficient tin-free reductive photochemical carboxymethylation of olefins with α-alkylthioacetates is developed, which (a) is an experimentally simple technique furnishing substituted derivatives of fatty acids in moderate to good yields, (b) is compatible with polar/protic functional groups and solvents, (c) does not require a special reducing reagent, (d) is fairly insensitive to the presence of dissolved oxygen and, generally, does not require degassing prior to irradiation. The critical feature of the mechanism is the 'reluctance' of short-lived MeS' to group- transfer, resulting in hydrogen abstraction from the media.

Reductive decyanation of α-cyano and α-alkoxycarbonyl substituted nitriles promoted by samarium(II) iodide

Decyanation of geminal dinitriles and α-alkoxycarbonyl substituted nitriles promoted by samarium(II) iodide has been efficiently achieved. This method has advantages over the previously known radical route using tin hydride with respect to applicable substrates and the reaction temperature employed. This decyanation could broaden the synthetic applicability of the nitrile derivatives.

Synthesis of ω-fluorinated octanoic acid and its β-substituted derivatives

Simple syntheses are described for the ω-fluorinated analogs of octanoic acid and its β-substituted derivatives in which insertion of a methyl and dimethyl group, and oxygen substitution at the C-3 position are involved, employing nucleophilic displacement with fluoride ion of the tosylate functions in the later stage of synthesis.The synthetic procedures offer easy and convenient acces to the corresponding 18F-labeled analogs using the readily available fluoride ion.

Synthesis of (+/-)-11-Hydroxy-trans-8-dodecenoic Acid

(+/-)-11-Hydroxy-trans-8-dodecenoic acid (2), an intermediate for the synthesis of recifeiolide, has been prepared starting from caprolactone and 1,3-butanediol.